<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Naloxone - Complete Profile</title>
    <link rel="stylesheet" href="/Dyo-s-Dubious-Domain/style.css">
    <link rel="icon" type="image/svg+xml" href="/Dyo-s-Dubious-Domain/assets/logo.svg">
    <script>
        // Set base path for JavaScript files to use
        window.SITE_BASE_PATH = '/Dyo-s-Dubious-Domain/';
    </script>
</head>

<body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/Dyo-s-Dubious-Domain/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/Dyo-s-Dubious-Domain/">Home</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/about/">About</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚ÜÅE<a href="/dyos-domain/depressants/">Depressants</a> ‚ÜÅE<span>Naloxone</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üöë Naloxone</h1>
        <h2 class="chemical-name">17-Allyl-4,5Œ±-epoxy-3,14-dihydroxymorphinan-6-one</h2>
          <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Naloxone" 
                data-category="Depressants" 
                data-chemical="17-Allyl-4,5Œ±-epoxy-3,14-dihydroxymorphinan-6-one">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Brand Names</h4>
              <span>Narcan</span> ‚Ä¢ <span>Evzio</span> ‚Ä¢ <span>Nyxoid</span> ‚Ä¢ <span>Prenoxad</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>The Revival</span> ‚Ä¢ <span>Comeback</span> ‚Ä¢ <span>Life Saver</span> ‚Ä¢ <span>Anti-Dope</span>
            </div>
            <div class="name-category">
              <h4>Clinical/Medical</h4>
              <span>Opioid Antagonist</span> ‚Ä¢ <span>Reversal Agent</span> ‚Ä¢ <span>Rescue Drug</span>
            </div>
            <div class="name-category">
              <h4>Chemical Abbreviations</h4>
              <span>NAL</span> ‚Ä¢ <span>Naloxone HCl</span> ‚Ä¢ <span>N-Allylnoroxymorphone</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category antidote">Antidote</span>
          <span class="legal-status otc">OTC/Rx</span>
          <span class="duration short">30-90 minutes</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/Dyo-s-Dubious-Domain/assets/substances/naloxone.jpg" alt="Naloxone nasal spray and autoinjector" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇÅ‚ÇâH‚ÇÇ‚ÇÅNO‚ÇÅE/p>
            <p>MW: 327.37 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pure Naloxone (HCl salt)</h4>
          <ul>
            <li><strong>Appearance:</strong> White to off-white crystalline powder</li>
            <li><strong>Texture:</strong> Fine crystalline solid</li>
            <li><strong>Odor:</strong> Odorless or nearly odorless</li>
            <li><strong>Taste:</strong> Bitter</li>
            <li><strong>Solubility:</strong> Freely soluble in water, slightly soluble in alcohol</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Commercial Forms</h4>
          <ul>
            <li><strong>Nasal Spray:</strong> 4mg/0.1mL (Narcan) - most common OTC form</li>
            <li><strong>Auto-injector:</strong> 0.4mg or 2mg (Evzio) - with voice instructions</li>
            <li><strong>Injectable:</strong> 0.4mg/mL, 1mg/mL vials (hospital/ambulance)</li>
            <li><strong>Prefilled syringes:</strong> Various concentrations for medical use</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†ÔøΩEÔøΩEAuthenticity Concerns</h4>
          <p><strong>Counterfeit Risk:</strong> Generally low for commercial products due to medical regulation</p>
          <p><strong>Expired Products:</strong> May have reduced efficacy but generally still effective</p>
          <p><strong>Storage Issues:</strong> Heat and light can degrade effectiveness</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Minimum</span>
          <span class="dose-amount">0.04mg IV</span>
          <span class="note">(pediatric)</span>
        </div>
        <div class="dose-range light">
          <span class="range-label">Standard IV</span>
          <span class="dose-amount">0.4-2mg</span>
          <span class="note">(medical setting)</span>
        </div>
        <div class="dose-range common">
          <span class="range-label">Nasal Spray</span>
          <span class="dose-amount">4mg</span>
          <span class="note">(single dose)</span>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Fentanyl OD</span>
          <span class="dose-amount">8-12mg</span>
          <span class="note">(multiple doses)</span>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Severe OD</span>
          <span class="dose-amount">20mg+</span>
          <span class="note">(hospital only)</span>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Administration Guidelines</h4>
        <ul>
          <li><strong>First Response:</strong> Start with one nasal spray (4mg) or 0.4mg IV</li>
          <li><strong>Repeat Dosing:</strong> Every 2-3 minutes if no response</li>
          <li><strong>Fentanyl Cases:</strong> Often requires multiple doses due to potency</li>
          <li><strong>Duration Concern:</strong> Naloxone shorter-acting than many opioids</li>
          <li><strong>Emergency Protocol:</strong> Always call 911, even if revival successful</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Critical Warning:</strong> Naloxone wears off in 30-90 minutes. Overdose can return when naloxone clears. Monitor continuously and seek medical attention.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline (Overdose Reversal)</h4>
        <div class="timeline-item">
          <span class="time">T+0:01-0:03</span>
          <span class="effect">Onset - breathing restoration (IV/IM)</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+0:02-0:08</span>
          <span class="effect">Onset - consciousness return (nasal)</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+0:05-0:15</span>
          <span class="effect">Peak effect - full opioid blockade</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+0:30-1:30</span>
          <span class="effect">Duration - protective effect wanes</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÅETherapeutic Effects</h4>
          <ul>
            <li>Immediate reversal of respiratory depression</li>
            <li>Restoration of consciousness</li>
            <li>Reversal of opioid-induced hypotension</li>
            <li>Restoration of normal pupil size</li>
            <li>Clearance of central nervous system depression</li>
            <li>Life-saving intervention</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùÅEPrecipitated Withdrawal Effects</h4>
          <ul>
            <li>Severe opioid withdrawal in dependent users</li>
            <li>Acute pain (if previously masked by opioids)</li>
            <li>Nausea and vomiting</li>
            <li>Anxiety and agitation</li>
            <li>Muscle aches and cramping</li>
            <li>Potential violence/confusion upon awakening</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Naloxone is a competitive mu-opioid receptor antagonist with high binding affinity but no intrinsic activity. It displaces opioid agonists from mu-opioid receptors (MOR), delta-opioid receptors (DOR), and kappa-opioid receptors (KOR), rapidly reversing opioid-mediated respiratory depression and CNS effects. Its competitive antagonism means it can be overcome by high concentrations of potent opioids like fentanyl.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œº-Opioid Receptor (MOR)</strong></span>
            <span class="affinity">Very high affinity (Ki: 1.1 nM)</span>
            <span class="function">Primary target - reverses euphoria, respiratory depression</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ¥-Opioid Receptor (DOR)</strong></span>
            <span class="affinity">High affinity (Ki: 18 nM)</span>
            <span class="function">Secondary effects on mood and analgesia</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ∫-Opioid Receptor (KOR)</strong></span>
            <span class="affinity">Moderate affinity (Ki: 119 nM)</span>
            <span class="function">Dysphoric effects, some analgesic reversal</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Toll-like Receptor 4 (TLR4)</strong></span>
            <span class="affinity">Weak antagonist activity</span>
            <span class="function">May reduce neuroinflammation (research stage)</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary Pathway:</strong> Hepatic glucuronidation via UGT enzymes</p>
          <p><strong>Active Metabolites:</strong> Naloxone-3-glucuronide (inactive)</p>
          <p><strong>Half-life:</strong> 30-90 minutes (IV), shorter than most opioids</p>
          <p><strong>Bioavailability:</strong> ~2% oral (high first-pass), 100% IV, ~40% intranasal</p>
          <p><strong>Peak plasma:</strong> 5-15 minutes (intranasal), immediate (IV)</p>
          <p><strong>Duration mismatch:</strong> Shorter than fentanyl, heroin, methadone - key clinical concern</p>
        </div>

        <h4>Competitive Antagonism Dynamics</h4>
        <div class="neurotoxicity-info">
          <p><strong>Receptor Competition:</strong> Higher opioid concentrations can overcome naloxone blockade</p>
          <p><strong>Dose-Response:</strong> Fentanyl overdoses often require multiple naloxone doses</p>
          <p><strong>Clearance Race:</strong> As naloxone clears, opioid effects can return</p>
          <p><strong>Withdrawal Precipitation:</strong> Immediate displacement causes acute withdrawal in dependent users</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <ul>
          <li><strong>Competitive antagonism:</strong> Can be overwhelmed by high-potency opioids</li>
          <li><strong>No agonist activity:</strong> Pure antagonist with no euphoric effects</li>
          <li><strong>Cross-tolerance immune:</strong> Effectiveness not reduced by opioid tolerance</li>
          <li><strong>Rapid onset:</strong> Life-saving speed of action via all routes</li>
          <li><strong>Safety profile:</strong> Extremely safe even in massive overdose</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†ÔøΩEÔøΩESafety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>Temporary effect:</strong> Overdose can return when naloxone wears off</li>
            <li><strong>Precipitated withdrawal:</strong> Can cause severe withdrawal in dependent users</li>
            <li><strong>Fentanyl resistance:</strong> May require multiple doses for synthetic opioids</li>
            <li><strong>Not a cure:</strong> Medical attention still required after use</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°ÔøΩEÔøΩEUsage Guidelines</h4>
          <ul>
            <li>Call 911 immediately, even if person revives</li>
            <li>Stay with person until medical help arrives</li>
            <li>Place person in recovery position if unconscious</li>
            <li>Be prepared for agitation/confusion upon revival</li>
            <li>Monitor for return of overdose symptoms</li>
            <li>Keep additional doses available</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Contraindications</h4>
        <p><strong>Extremely rare:</strong> Known hypersensitivity to naloxone. Benefits virtually always outweigh risks in overdose situations. Safe in pregnancy, children, elderly.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏ÅEDrug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Critical Interactions</h4>
          <ul>
            <li><strong>All Opioids:</strong> Primary therapeutic target - reverses effects</li>
            <li><strong>Partial Agonists:</strong> May precipitate withdrawal (buprenorphine)</li>
            <li><strong>Mixed Agonist-Antagonists:</strong> Complex interactions with pentazocine, butorphanol</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° Clinical Considerations</h4>
          <ul>
            <li><strong>Clonidine:</strong> Withdrawal symptoms may be more severe</li>
            <li><strong>CNS Depressants:</strong> May unmask non-opioid depression (alcohol, benzos)</li>
            <li><strong>Stimulants:</strong> May reveal underlying stimulant intoxication</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Monitoring Required</h4>
          <ul>
            <li><strong>Cardiac medications:</strong> Withdrawal stress may affect heart conditions</li>
            <li><strong>Anticoagulants:</strong> Injection site bleeding risk</li>
            <li><strong>Psychiatric medications:</strong> Acute withdrawal may worsen mental health</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏ÅELegal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE United States</h4>
            <p><strong>OTC Available</strong> - Narcan nasal spray available without prescription in most states. Good Samaritan laws protect users and those who call for help.</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE United Kingdom</h4>
            <p><strong>Pharmacy Medicine</strong> - Available from pharmacies without prescription. Supported by needle exchange programs.</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE Canada</h4>
            <p><strong>Non-prescription</strong> - Widely available, distributed through harm reduction programs and pharmacies.</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE Australia</h4>
            <p><strong>Pharmacy/OTC</strong> - Available through pharmacy and take-home naloxone programs.</p>
          </div>
        </div>
        
        <div class="therapeutic-status">
          <h4>üè• Medical Status</h4>
          <p>Essential medicine recognized by WHO. Increasingly available without prescription as part of global overdose prevention initiatives. Protected by Good Samaritan laws in many jurisdictions.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1961</span>
          <p>First synthesized by Mozes J. Lewenstein and Jack Fishman at Endo Laboratories</p>
        </div>
        <div class="history-event">
          <span class="year">1971</span>
          <p>FDA approves naloxone for medical use in opioid overdose</p>
        </div>
        <div class="history-event">
          <span class="year">1996</span>
          <p>First community-based overdose prevention programs begin in Chicago</p>
        </div>
        <div class="history-event">
          <span class="year">2001</span>
          <p>New Mexico becomes first state to expand naloxone access</p>
        </div>
        <div class="history-event">
          <span class="year">2015</span>
          <p>FDA approves Narcan nasal spray for over-the-counter use</p>
        </div>
        <div class="history-event">
          <span class="year">2018</span>
          <p>All 50 US states have naloxone access laws</p>
        </div>
        <div class="history-event">
          <span class="year">2023</span>
          <p>Over 3 million overdose reversals reported in US</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Cultural Impact</h4>
        <p>Naloxone has transformed harm reduction culture, shifting from a purely medical intervention to a community empowerment tool. It represents the first line of defense in the opioid crisis and has saved countless lives while reducing stigma around drug use by focusing on preservation of life over criminalization.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Extended-Release Formulations</h4>
          <p>Development of longer-acting naloxone formulations to match the duration of potent synthetic opioids like fentanyl.</p>
        </div>
        
        <div class="research-item">
          <h4>Abuse-Deterrent Combinations</h4>
          <p>Research into combining naloxone with prescription opioids to prevent abuse while maintaining therapeutic effects.</p>
        </div>
        
        <div class="research-item">
          <h4>Novel Delivery Methods</h4>
          <p>Investigation of wearable auto-injectors and implantable devices for high-risk individuals.</p>
        </div>
        
        <div class="research-item">
          <h4>Neuroprotective Effects</h4>
          <p>Studies on naloxone's potential protective effects against opioid-induced brain damage and hypoxic injury.</p>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Access & Training</h4>
        <ul>
          <li><a href="https://getnaloxonenow.org/">GetNaloxoneNow.org</a> - Find naloxone near you</li>
          <li><a href="https://nextdistro.org/">NEXT Distro</a> - Mail-order harm reduction supplies</li>
          <li><a href="https://prescribetoprevent.org/">Prescribe to Prevent</a> - Healthcare provider resources</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Education & Training</h4>
        <ul>
          <li><a href="https://harmreduction.org/">Harm Reduction Guide</a> - Training materials</li>
          <li><a href="https://stopoverdose.org/">Stop Overdose</a> - Recognition and response</li>
          <li><a href="https://www.samhsa.gov/medication-assisted-treatment/naloxone">SAMHSA</a> - Official government resources</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Support & Community</h4>
        <ul>
          <li><a href="https://neverusealone.com/">Never Use Alone</a> - Overdose prevention hotline</li>
          <li><a href="https://www.reddit.com/r/OpiatesRecovery/">/r/OpiatesRecovery</a> - Recovery support community</li>
          <li><a href="https://www.reddit.com/r/harmreduction/">/r/HarmReduction</a> - Harm reduction discussion</li>
        </ul>
      </div>
    </div>
  </div>

</div>


    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/Dyo-s-Dubious-Domain/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/Dyo-s-Dubious-Domain/js/lunr.min.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/search.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/substance-integration.js"></script>
    
    <!-- Only load profile.js on profile page -->
    
</body>
</html>